A kind of metformin hydrochloride sustained-release empagliflozin immediate-release micropill and preparation method thereof

Metformin hydrochloride sustained-release empagliflozin rapid-release microgranules prepared using multi-layer coating technology solve the release mismatch problem between metformin hydrochloride and empagliflozin combination preparations, reduce gastrointestinal reactions, stabilize blood glucose levels, and improve patient compliance.

CN114469896BActive Publication Date: 2024-11-08JIANGSU WANBANG BIOPHARMLS

Patent Information

Application Number
CN202011154208.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2020-10-26
Publication Date
2024-11-08
Estimated Expiration
2040-10-26

AI Technical Summary

Technical Problem

In the existing technology, the combination formulation of metformin hydrochloride and empagliflozin cannot simultaneously achieve slow release of metformin hydrochloride and rapid release of empagliflozin, resulting in greater gastric irritation and significant differences in blood drug concentration among different patients, which affects treatment efficacy and patient compliance.

Method used

A metformin hydrochloride sustained-release empagliflozin rapid-release microgranule was prepared by using a multi-layer coating technology, including a blank pellet core, a drug-containing layer, an isolation layer, and a sustained-release coating layer, to control the release rate and stability of the drug, ensuring slow release of metformin hydrochloride and rapid release of empagliflozin.

Benefits of technology

It reduced gastrointestinal reactions, stabilized fasting blood glucose levels, improved patient compliance, avoided differences in blood drug concentration, and achieved stable drug release and sustained therapeutic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure HDA0002742214170000011
    Figure HDA0002742214170000011
Patent Text Reader

Abstract

The present invention discloses a metformin hydrochloride sustained-release empagliflozin immediate-release micropill and a preparation method thereof. The micropill comprises a blank core, a drug-containing layer 1, an isolation layer 1, a sustained-release coating layer 1, an isolation layer 2, a drug-containing layer 2, and an isolation layer 3 from the inside to the outside; the weight ratio of the main drug metformin hydrochloride: empagliflozin is (40-200):1. The metformin hydrochloride sustained-release empagliflozin immediate-release micropill prepared by the present invention can ensure the slow release of metformin hydrochloride while controlling the rapid release of empagliflozin. The daily dosage can be ensured to be 1 time / day, which reduces the number of medications and improves patient compliance.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of pharmaceutical preparations, and discloses a pharmaceutical compound preparation for treating and / or improving type II diabetes and a preparation method thereof, and specifically relates to a metformin hydrochloride sustained-release empagliflozin immediate-release micropill and a preparation method thereof. Background Art

[0002] In a broad sense, diabetes is divided into type 1 and type 2, with type 2 accounting for more than 90% of all diabetic patients. Type 2 diabetes is a lifelong disease that usually begins in middle age or later in life, but can begin at any age.

[0003] Diabetes is caused by the inability to control blood sugar in the patient's body. Diabetes increases the risk of heart disease, stroke, blindness, kidney failure and amputation. Therefore, the current goal of diabetes treatment is to achieve and maintain blood sugar as close to normal as possible to prevent long-term microvascular and macrovascular complications related to elevated blood sugar.

[0004] Metformin hydrochloride is a common initial treatment drug for type 2 diabetes. It can reduce the production of glycogen, reduce the absorption of glucose by the small intestine, and increase insulin sensitivity by increasing the uptake and utilization of glucose by peripheral tissues. Unlike sulfonylurea drugs, metformin hydrochloride will not cause hypoglycemia in patients with type 2 diabetes or patients with normal blood sugar. Metformin promotes the binding of insulin to receptors and increases the sensitivity of diabetic patients to insulin, increases the anaerobic glycolysis of sugar by peripheral tissues and promotes the utilization of sugar, inhibits fat decomposition, reduces plasma free fatty acid levels, weakens insulin resistance and improves the utilization of glucose, thereby playing a role in lowering blood sugar, lowering blood lipids, and inhibiting arteriosclerosis. Metformin hydrochloride has become the first choice drug for patients with mild to moderate type 2 diabetes, especially obese type 2 diabetes patients.

[0005] Empagliflozin is an emerging class of hypoglycemic drugs called sodium-glucose co-transporter-2 (SGLT-2) inhibitors that can block the reabsorption of glucose in the kidneys and excrete excess glucose out of the body, thereby achieving the effect of lowering blood sugar. Moreover, this hypoglycemic effect is independent of β-cell function and insulin resistance.

[0006] In the prior art, there are also reports on the use of metformin hydrochloride and empagliflozin as compound preparations, such as Chinese patent 201710123019.9, a pharmaceutical composition containing empagliflozin and metformin hydrochloride, but due to preparation problems, it is impossible to achieve the requirements of slow release of metformin hydrochloride and rapid release of empagliflozin. The ordinary preparation of metformin hydrochloride has a fast dissolution rate in the stomach, which is relatively irritating to the stomach. After swelling, the metformin sustained-release preparation slowly dissolves, so that the contained drug is constantly and continuously released, and the effective and stable blood drug concentration is maintained for a long time. Studies have found that there is no significant difference in fasting and 2 hours after meal blood sugar, glycosylated hemoglobin, total cholesterol, triglycerides and high-density lipoprotein in different patients after treatment with sustained-release tablets and ordinary tablets; and the reduction of low-density lipoprotein in the sustained-release tablet group is greater than that in the ordinary tablet group. This shows that the sustained-release preparation has practical significance for reducing the cardiovascular risk of patients with type 2 diabetes. At the same time, due to the stable blood drug concentration, it is relatively good for controlling fasting blood sugar. Based on this, a micropellet preparation was developed that can control the slow release of metformin hydrochloride, which is easily soluble in water, and ensure the rapid release of empagliflozin, which is poorly soluble, so that it has the desired dissolution rate and stability. Summary of the invention

[0007] In view of the above problems, the present invention prepares a metformin hydrochloride sustained-release empagliflozin rapid-release micropill, which can ensure the slow release of metformin hydrochloride while controlling the rapid release of empagliflozin. This dosage form can not only reduce the gastrointestinal reaction of metformin hydrochloride, but also better control fasting blood sugar. The micropill can be prepared to avoid the influence of tablet hardness difference on blood drug concentration. The daily dosage can be guaranteed to be 1 time / day, which reduces the number of medications and improves patient compliance.

[0008] Another object of the present invention is to provide a method for preparing the above-mentioned sustained-release pellets.

[0009] In order to solve the above technical problems, the present invention is implemented through the following technical solutions:

[0010] The present invention provides a metformin hydrochloride sustained-release-empagliflozin immediate-release micropill, which comprises a blank core, a drug-containing layer 1, an isolation layer 1, a sustained-release coating layer 1, an isolation layer 2, a drug-containing layer 2, and an isolation layer 3 from the inside to the outside; the weight ratio of the main drug metformin hydrochloride:empagliflozin is (40-200):1.

[0011] In some embodiments, the blank pellet cores of the present invention are selected from one or more of microcrystalline cellulose pellet cores, starch pellet cores, pre-coated starch pellet cores, and sucrose pellet cores.

[0012] In some embodiments, the weight percentage of metformin hydrochloride in the drug-containing layer 1 is 65% to 85%, preferably 75% to 85%; in some embodiments, the drug-containing layer 1 also includes one or more of hydroxypropyl cellulose, talc, silicon dioxide, and water; preferably contains hydroxypropyl cellulose and talc.

[0013] In some specific embodiments, the drug-containing layer 1 comprises the following substances in parts by weight: 75-85 parts of metformin hydrochloride, 2-5 parts of hydroxypropyl cellulose and 0.3-0.7 parts of talc; preferably, 78-81 parts of metformin hydrochloride, 2.5-4 parts of hydroxypropyl cellulose and 0.4-0.6 parts of talc.

[0014] The weight gain of drug-containing layer 1 can be calculated according to the amount of drug.

[0015] In some embodiments, the weight percentage of empagliflozin in the drug-containing layer 2 is 0.2% to 2%, preferably 0.3% to 1.8%; in some embodiments, the drug-containing layer 2 further includes one or more of hydroxypropyl cellulose, talc, silicon dioxide, and water; preferably, it contains hydroxypropyl cellulose and talc.

[0016] In some specific embodiments, the drug-containing layer 2 comprises the following substances in parts by weight: 0.2-2 parts of empagliflozin, 0.3-2 parts of hydroxypropyl cellulose, and 0.05-0.4 parts of talc; preferably, 0.2-1.8 parts of empagliflozin, 0.4-1.5 parts of hydroxypropyl cellulose, and 0.05-0.3 parts of talc.

[0017] The weight gain range of the drug-containing layer 2 can be calculated according to the dosage of the drug.

[0018] In some embodiments, the isolation layer 1, isolation layer 2 and isolation layer 3 may be the same or different in the same formulation, and the isolation layer coating liquid is one or more of Opadry EC, polyethylene glycol, hypromellose, talc, magnesium stearate or water, preferably Opadry EC.

[0019] In some embodiments, the weight gain range of the isolation layer 1, the isolation layer 2 and the isolation layer 3 is 0.5% to 5%, preferably 1% to 5%.

[0020] In some embodiments, the ingredients of the sustained-release coating layer 1 include one or more of ethylcellulose dispersion, hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, and hydroxypropyl cellulose, preferably ethylcellulose dispersion and hydroxypropyl methylcellulose.

[0021] In a specific embodiment, the sustained-release coating layer 1 comprises the following ingredients in parts by weight: 7 to 10 parts of ethyl cellulose dispersion and 0.3 to 0.6 parts of hypromellose.

[0022] In some embodiments, the weight gain range of the sustained-release coating layer 1 is 5% to 20%, preferably 8% to 15%.

[0023] The present invention also provides a method for preparing the above-mentioned metformin hydrochloride sustained-release-empagliflozin immediate-release pellets, comprising the following steps:

[0024] (1) Preparation of drug-containing layer 1:

[0025] Add the formulated amount of hydroxypropyl cellulose to purified water and stir evenly. After the mixture is completely dissolved, add the formulated amount of metformin hydrochloride and talcum powder in sequence. Stir evenly to obtain a metformin hydrochloride solution. Spray the solution onto the blank pill core to obtain drug-containing layer 1 pellets.

[0026] (2) Preparation of isolation layer 1:

[0027] Add the coating solution of the formula amount into purified water and stir evenly to obtain the coating solution of isolation layer 1, and spray the coating solution of isolation layer 1 onto the drug-containing layer 1 micropellets prepared in step (1) to complete the coating of isolation layer 1;

[0028] (3) Preparation of sustained-release coating layer 1:

[0029] Under stirring, the ingredients of the sustained-release coating layer 1 in the formula amount are added to purified water in sequence or simultaneously and stirred evenly to obtain a sustained-release coating solution, and the sustained-release coating solution is sprayed onto the isolation layer 1 to obtain sustained-release coating layer 1 pellets;

[0030] (4) Preparation of isolation layer 2:

[0031] Add the coating solution of the formula amount into purified water and stir evenly to obtain the coating solution of the isolation layer 2, and spray the coating solution of the isolation layer 2 onto the sustained-release coating layer 1 micropellets prepared in step (3) to complete the coating of the isolation layer 2;

[0032] (5) Preparation of drug-containing layer 2:

[0033] Add the formulated amount of hydroxypropyl cellulose to purified water under stirring and stir evenly, add the formulated amount of empagliflozin and talcum powder in sequence after they are completely dissolved, stir evenly to obtain empagliflozin solution, and spray-coat the isolation layer 2 with the above solution to obtain drug-containing layer 2 pellets;

[0034] (6) Preparation of isolation layer 3:

[0035] Add the formulated amount of coating liquid into purified water and stir evenly to obtain the coating liquid for isolation layer 3. Spray the coating liquid for isolation layer 3 onto the drug-containing layer 2 micropellets prepared in step (5) to complete the coating of isolation layer 3.

[0036] The preparation method of the present invention and the formula of each layer are as described above.

[0037] In a specific embodiment of the present invention, the present invention also provides a more specific method for preparing metformin hydrochloride sustained-release-empagliflozin immediate-release pellets, the steps of which are as follows:

[0038] (1) Prescription and preparation of drug-containing pellets 1:

[0039] Excipients Dosage Metformin Hydrochloride 78%~81% Blank pellets 12%~17% Hydroxypropyl Cellulose 2.5%~4% talcum powder 0.4%~0.6%

[0040] ① Add the hydroxypropyl cellulose to purified water under stirring and stir evenly for later use;

[0041] ② Add metformin hydrochloride and talcum powder in sequence, and stir evenly to obtain metformin hydrochloride solution;

[0042] ③ Spray the above-mentioned drug solution onto the blank pill core to obtain drug-containing layer 1 micropellets, and dry them.

[0043] (2) Prescription and preparation of isolated pellets 1:

[0044]

[0045]

[0046] ① Add the above Opadry into purified water and stir evenly for later use;

[0047] ② Spray the above-mentioned Opadry coating solution onto the above-mentioned drug-containing layer 1 micropellets to complete the isolation layer 1 micropellets;

[0048] (3) Prescription of sustained-release pellets 1

[0049] Excipients Dosage Isolate Pellets 1 85%~92% Ethyl cellulose dispersion 7%~10% Hydroxypropyl methylcellulose 0.3%~0.6%

[0050] ① Add the ethyl cellulose dispersion and hypromellose to purified water in sequence under stirring, stir evenly, and set aside;

[0051] ② Spray the coating solution onto the isolation layer 1 pellets to obtain sustained-release coating layer 1 pellets;

[0052] (4) Prescription of Isolation Pellets 2

[0053] Excipients Dosage Sustained release pellets 1 96%~99% Obaday 2.5%~4%

[0054] ① Add the above Opadry into purified water and stir evenly for later use;

[0055] ② Spray the above Opadry coating solution onto the above sustained-release coating layer 1 pellets to complete the isolation layer 2 pellets;

[0056] (5) Prescription of 2 medicated pellets

[0057] Excipients Dosage Isolate Pellets 2 96%~99% Empagliflozin 0.2%~1.8% Hydroxypropyl Cellulose 0.4%~1.5% talcum powder 0.05%~0.3%

[0058] ① Add the hydroxypropyl cellulose to purified water under stirring and stir evenly for standby use;

[0059] ② Add empagliflozin and talcum powder in sequence, and stir evenly to obtain empagliflozin solution;

[0060] ③ Spray the above-mentioned drug solution onto the isolation layer 2 micropellets, and dry them to obtain the drug-containing layer 2 micropellets;

[0061] (6) Prescription of Isolation Pellets 3:

[0062] Excipients Dosage Drug-containing pellets 2 96%~99% Obaday 2.5%~4%

[0063] ① Add the above Opadry into purified water and stir evenly for later use;

[0064] ② Spray the above-mentioned Opadry coating solution onto the above-mentioned drug-containing layer 2 micropellets to complete the isolation layer 3 coating.

[0065] The advantages of the micro-pellets of the present invention over the prior art are:

[0066] ① Reduce the gastrointestinal reactions presented by common dosage forms;

[0067] ②Can better control fasting blood sugar;

[0068] ③ Micropills are easy to swallow and patients can easily accept them, which can improve compliance;

[0069] ④ Prepared into micropellets, there will be no difference in blood drug concentration due to differences in tablet hardness. BRIEF DESCRIPTION OF THE DRAWINGS

[0070] Figure 1 is the dissolution curve of the reference sample empagliflozin in pH 1.2 buffer;

[0071] Figure 2 is the dissolution curve of the reference sample metformin in pH 1.2 buffer;

[0072] Figure 3 is the release curve of empagliflozin in pH 1.2 buffer of Examples 1 and 2 of the present invention;

[0073] Figure 4 This is the release curve of metformin hydrochloride in Examples 1 and 2 of the present invention in pH 1.2 buffer. DETAILED DESCRIPTION

[0074] The present invention will be further described in detail below in conjunction with the accompanying drawings and examples. The experimental methods in the following examples are conventional methods unless otherwise specified. The test materials used in the following examples are purchased from conventional biochemical reagent stores unless otherwise specified.

[0075] Example 1

[0076] Step 1: Preparation of metformin hydrochloride sustained-release pellets

[0077] (1) Preparation of drug-containing layer 1:

[0078] Under stirring, add the formulated amount of hydroxypropyl cellulose to purified water and stir evenly. After complete dissolution, add metformin hydrochloride and talcum powder in sequence, stir evenly to obtain metformin hydrochloride solution, and spray the above solution on the blank pill core to obtain drug-containing layer 1.

[0079] The weight percentage of each component in the drug-containing layer 1 is as follows: blank pill core accounts for 15.3%, metformin hydrochloride accounts for 80.6%, hydroxypropyl cellulose accounts for 3.5%, and talc accounts for 0.6%.

[0080] (2) Preparation of isolation layer 1

[0081] Opadry EC was added into purified water and stirred evenly, wherein the concentration of Opadry was 1.2%. The Opadry EC was used as the isolation layer coating liquid. The isolation layer coating liquid was sprayed onto the above-mentioned drug-containing layer 1 micropellets to complete the isolation layer 1 coating.

[0082] The weight gain of the isolation layer 1 was 1%.

[0083] (3) Preparation of sustained-release coating layer 1

[0084] The ethyl cellulose dispersion and hydroxypropyl methylcellulose are sequentially added into purified water under stirring and stirred evenly to form a sustained-release layer coating liquid. The sustained-release layer coating liquid is spray-coated on the isolation layer 1 to obtain metformin hydrochloride sustained-release micropellets.

[0085] The weight proportions of each substance in the sustained-release coating layer 1 are as follows: 8.7 parts of ethyl cellulose dispersion and 0.4 parts of hydroxypropyl methylcellulose. The sustained-release coating layer 1 has a weight gain of 8%.

[0086] (4) Preparation of isolation layer 2

[0087] Opadry was added into purified water and stirred evenly, wherein the concentration of Opadry was 2.8%. The isolation layer coating liquid was sprayed onto the sustained-release coating layer 1 micropellets to complete the isolation layer 2 coating.

[0088] The weight gain of the isolation layer 2 was 3%.

[0089] Step 2: Preparation of empagliflozin immediate-release pellets

[0090] (5) Preparation of drug-containing layer 2:

[0091] The hydroxypropyl cellulose is added to purified water under stirring and stirred evenly. After being completely dissolved, empagliflozin and talcum powder are added in sequence and stirred evenly to obtain empagliflozin solution. The above solution is spray-coated on the metformin hydrochloride sustained-release micropellets to obtain drug-containing layer 2.

[0092] The weight proportions of the substances in the drug-containing layer 2 are: 0.3% for empagliflozin, 1.4% for hydroxypropyl cellulose, and 0.2% for talc.

[0093] (6) Preparation of isolation layer 3

[0094] Add the formulated amount of Opadry into purified water and stir evenly, wherein the concentration of Opadry is 2.6%. Spray the coating liquid of isolation layer 3 onto the above-mentioned drug-containing layer 2 micropellets as the coating liquid of isolation layer 3 to complete the coating of isolation layer 3.

[0095] The weight of the isolation layer 3 increased by 3%.

[0096] Example 2

[0097] Step 1: Preparation of metformin hydrochloride sustained-release pellets

[0098] (1) Preparation of drug-containing layer 1:

[0099] Under stirring, add the formulated amount of hydroxypropyl cellulose to purified water and stir evenly. After complete dissolution, add metformin hydrochloride and talcum powder in sequence, stir evenly to obtain metformin hydrochloride solution, and spray the above solution on the blank pill core to obtain drug-containing layer 1.

[0100] The weight percentage of each component in the drug-containing layer 1 is as follows: blank pill core accounts for 15.3%, metformin hydrochloride accounts for 80.6%, hydroxypropyl cellulose accounts for 3.5%, and talc accounts for 0.6%.

[0101] (2) Preparation of isolation layer 1

[0102] Opadry was added into purified water and stirred evenly, wherein the concentration of Opadry was 1.2%. The Opadry was used as the isolation layer coating liquid. The isolation layer coating liquid was sprayed onto the above-mentioned drug-containing layer 1 micropills to complete the isolation layer 1 coating.

[0103] The weight gain of the isolation layer 1 was 1%.

[0104] (3) Preparation of sustained-release coating layer 1

[0105] The ethyl cellulose dispersion and hydroxypropyl methylcellulose are sequentially added into purified water under stirring and stirred evenly to form a sustained-release layer coating liquid. The sustained-release layer coating liquid is spray-coated on the isolation layer 1 to obtain metformin hydrochloride sustained-release micropellets.

[0106] The weight percentage of each substance in the sustained-release coating layer 1 is: 8.7 parts of ethyl cellulose dispersion and 0.4 parts of hydroxypropyl methylcellulose. The sustained-release coating layer 1 has a weight gain of 8%

[0107] (4) Preparation of isolation layer 2

[0108] Opadry was added into purified water and stirred evenly, wherein the concentration of Opadry was 2.8%. The isolation layer coating liquid was sprayed onto the sustained-release coating layer 1 micropellets to complete the isolation layer 2 coating.

[0109] The weight gain of the isolation layer 2 was 3%.

[0110] Step 2: Preparation of empagliflozin immediate-release pellets

[0111] (5) Preparation of drug-containing layer 2:

[0112] The hydroxypropyl cellulose is added to purified water under stirring and stirred evenly. After being completely dissolved, empagliflozin and talcum powder are added in sequence and stirred evenly to obtain empagliflozin solution. The above solution is spray-coated on the metformin hydrochloride sustained-release micropellets to obtain drug-containing layer 2.

[0113] The weight proportions of the substances in the drug-containing layer 2 are: 0.9 for empagliflozin, 0.9 for hydroxypropyl cellulose, and 0.1 for talc.

[0114] (6) Preparation of isolation layer 3

[0115] Add the formulated amount of Opadry into purified water and stir evenly, wherein the concentration of Opadry is 2.6%. Spray the coating liquid of isolation layer 3 onto the above-mentioned drug-containing layer 2 micropellets as the coating liquid of isolation layer 3 to complete the coating of isolation layer 3.

[0116] The weight of the isolation layer 3 increased by 3%.

[0117] Comparison with existing technologies:

[0118] The existing composite tablet information and dissolution method are as follows, and the dissolution curve is as follows Figure 1 and Figure 2 As shown:

[0119] Reference sample information:

[0120] Generic name: Compound Empagliflozin Metformin Tablets

[0121] Manufacturer: Boehringer Ingelheim and Eli Lilly

[0122] Specification: 1000mg / 5mg

[0123] Batch number: 502210

[0124] Release test method: Paddle method, 50rpm / min, release medium is pH1.2 buffer salt 900ml

[0125] Detection method: HPLC

[0126] Sampling time points: Empagliflozin: 5min, 10min, 15min, 20min, 30min

[0127] Metformin hydrochloride: 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h

[0128] The release curves of empagliflozin and metformin hydrochloride in the metformin hydrochloride sustained-release-empagliflozin immediate-release pellets prepared in Example 1 and Example 2 in a pH 1.2 buffer solution are as follows: Figure 3 and Figure 4 shown.

Claims

1. A metformin hydrochloride sustained-release-empagliflozin immediate-release pellet, characterized in that: The micropellets are composed of a blank core, a drug-containing layer 1, an isolation layer 1, a sustained-release coating layer 1, an isolation layer 2, a drug-containing layer 2, and an isolation layer 3 from the inside to the outside; The drug-containing layer 1 is composed of the following materials in parts by weight: 75-85 parts of metformin hydrochloride, 2-5 parts of hydroxypropyl cellulose and 0.3-0.7 parts of talc; The drug-containing layer 2 is composed of the following materials in parts by weight: 0.2-2 parts of empagliflozin, 0.3-2 parts of hydroxypropyl cellulose, and 0.05-0.4 parts of talc; The isolation layer coating liquid used for isolation layer 1, isolation layer 2 and isolation layer 3 is Opadry; the weight gain range of isolation layer 1, isolation layer 2 and isolation layer 3 is 1% to 5%; The sustained-release coating layer 1 is composed of ethyl cellulose dispersion and hypromellose, wherein the ethyl cellulose dispersion is 7 to 10 parts by weight and the hypromellose is 0.3 to 0.6 parts by weight; the weight gain range of the sustained-release coating layer 1 is 5% to 20%.

2. The metformin hydrochloride sustained-release-empagliflozin immediate-release pellets according to claim 1, characterized in that: The blank pill core is selected from one or more of microcrystalline cellulose pill core, starch pill core and sucrose pill core.

3. The metformin hydrochloride sustained-release-empagliflozin immediate-release pellets according to claim 1, characterized in that: The drug-containing layer 1 is composed of the following materials in parts by weight: 78-81 parts of metformin hydrochloride, 2.5-4 parts of hydroxypropyl cellulose and 0.4-0.6 parts of talc.

4. The metformin hydrochloride sustained-release-empagliflozin immediate-release pellets according to claim 1, characterized in that: The drug-containing layer 2 is composed of the following materials in parts by weight: 0.2-1.8 parts of empagliflozin, 0.4-1.5 parts of hydroxypropyl cellulose and 0.05-0.3 parts of talc.

5. The metformin hydrochloride sustained-release-empagliflozin immediate-release pellets according to claim 1, characterized in that: The weight gain range of the sustained-release coating layer 1 is 8% to 15%.

6. The method for preparing the metformin hydrochloride sustained-release-empagliflozin immediate-release pellets according to any one of claims 1 to 5, comprising the following steps: (1) Preparation of drug-containing layer 1: Add the formulated amount of hydroxypropyl cellulose to purified water and stir evenly. After the mixture is completely dissolved, add the formulated amount of metformin hydrochloride and talcum powder in sequence. Stir evenly to obtain a metformin hydrochloride solution. Spray the solution onto the blank pill core to obtain drug-containing layer 1 pellets. (2) Preparation of isolation layer 1: Add the coating solution of the formula amount into purified water and stir evenly to obtain the coating solution of isolation layer 1, and spray the coating solution of isolation layer 1 onto the drug-containing layer 1 micropellets prepared in step (1) to complete the coating of isolation layer 1; (3) Preparation of sustained-release coating layer 1: Under stirring, the ingredients of the sustained-release coating layer 1 in the formula amount are added to purified water in sequence or simultaneously and stirred evenly to obtain a sustained-release coating solution, and the sustained-release coating solution is sprayed onto the isolation layer 1 to obtain sustained-release coating layer 1 pellets; (4) Preparation of isolation layer 2: Add the coating solution of the formula amount into purified water and stir evenly to obtain the coating solution of the isolation layer 2, and spray the coating solution of the isolation layer 2 onto the sustained-release coating layer 1 micropellets prepared in step (3) to complete the coating of the isolation layer 2; (5) Preparation of drug-containing layer 2: Add the formulated amount of hydroxypropyl cellulose to purified water under stirring and stir evenly, add the formulated amount of empagliflozin and talcum powder in sequence after they are completely dissolved, stir evenly to obtain empagliflozin solution, and spray-coat the isolation layer 2 with the above solution to obtain drug-containing layer 2 pellets; (6) Preparation of isolation layer 3: Add the formulated amount of coating liquid into purified water and stir evenly to obtain the coating liquid for isolation layer 3. Spray the coating liquid for isolation layer 3 onto the drug-containing layer 2 micropellets prepared in step (5) to complete the coating of isolation layer 3.

Citation Information

Patent Citations

  • Medicine composition containing empagliflozin and dimethylbiguanide hydrochloride

    CN106924237A

  • Method for preparing metformin hydrochloride controlled-release pellet preparation

    CN103417496A

  • Sitagliptin and melbine compound sustained-release preparation and preparation method thereof

    CN103655570A

  • Metformin hydrochloride enteric-coated sustained-release pellet and preparation method thereof

    CN104434846A

  • Saxagliptin micro-pill and preparation method thereof

    CN105796503A

Cited By

  • S-equol biphasic release pellets and methods of making same

    CN122786315A